Intercept Pharmaceuticals (NAS:ICPT) Asset Turnover

: 0.13 (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Intercept Pharmaceuticals's Revenue for the three months ended in Mar. 2023 was $68.0 Mil. Intercept Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2023 was $528.9 Mil. Therefore, Intercept Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2023 was 0.13.

Asset Turnover is linked to ROE % through Du Pont Formula. Intercept Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2023 was -160.41%. It is also linked to ROA % through Du Pont Formula. Intercept Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2023 was -24.30%.

Intercept Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Intercept Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Turnover

0.36

0.40

0.35

0.47

0.53

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Asset Turnover																0.12	0.14	0.15	0.14	0.13

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Asset Turnover Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Asset Turnover falls in comparison to its industry or sector. The grey bar indicates the Asset Turnover's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Intercept Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
=	285.71	/	( (527.023	+	553.711)	/ 2 )
=	285.71	/	540.367
=	0.53

Intercept Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2023 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (Q: Mar. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
=	67.958	/	( (553.711	+	504.085)	/ 2 )
=	67.958	/	528.898
=	0.13

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Intercept Pharmaceuticals (NAS:ICPT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Intercept Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2023 is

	ROE %^**		(Q: Mar. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-128.54	/	80.131
=	(Net Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-128.54 / 271.832)	*	(271.832 / 528.898)	*	(528.898/ 80.131)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-47.29 %	*	0.514	*	6.6004
=	ROA %	*	Equity Multiplier
=	-24.30 %	*	6.6004
=	-160.41 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Intercept Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2023 is

	ROA %		(Q: Mar. 2023 )
=	Net Income	/	Total Assets
=	-128.54	/	528.898
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(-128.54 / 271.832)	*	(271.832 / 528.898)
=	Net Margin %	*	Asset Turnover
=	-47.29 %	*	0.514
=	-24.30 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Intercept Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Asset Turnover

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451